Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior.
BACKGROUND
Investigations of nucleotide signaling in nociception to date have focused on actions of adenosine triphosphate (ATP). Both ATP-gated ion channels (P2X receptors) and G protein-coupled (P2Y) receptors contribute to nociceptive signaling in peripheral sensory neurons. In addition, several studies have implicated the Gq-coupled adenosine diphosphate (ADP) receptor P2Y1 in sensory transduction. In this study, we examined the expression and function of P2Y1 and the Gi-coupled receptors P2Y12, P2Y13 and P2Y14 in sensory neurons to determine their contribution to nociception.


RESULTS
We detected mRNA and protein for ADP receptors P2Y12 and P2Y13 in mouse dorsal root ganglia (DRG). P2Y14, a homologous Gi-coupled nucleotide receptor, is also expressed in DRG. Immunohistochemical analysis of receptor distribution indicated that these receptors are widely expressed in nociceptive neurons. Using ratiometric calcium imaging, we found that ADP evokes increases in intracellular calcium in isolated DRG neurons and also produces a pertussis toxin-sensitive inhibition of depolarization-evoked calcium transients. The inhibitory effect of ADP was unaltered in the presence of the selective P2Y1 antagonist MRS2179 and in neurons isolated from P2Y1 knockout mice, whereas ADP-evoked calcium transients were greatly reduced. Analysis of behavioral responses to noxious heat before and after inflammatory injury (injection of complete Freund's adjuvant into the hindpaw) revealed that P2Y1 is required for the full expression of inflammatory hyperalgesia, whereas local injection of agonists for Gi-coupled P2Y receptors reduced hyperalgesia.


CONCLUSIONS
We report that Gi-coupled P2Y receptors are widely expressed in peripheral sensory neurons. Agonists for these receptors inhibit nociceptive signaling in isolated neurons and reduce behavioral hyperalgesia in vivo. Anti-nociceptive actions of these receptors appear to be antagonized by the Gq-coupled ADP receptor, P2Y1, which is required for the full expression of inflammatory hyperalgesia. We propose that nociceptor sensitivity is modulated by the integration of nucleotide signaling through Gq- and Gi-coupled P2Y receptors, and this balance is altered in response to inflammatory injury. Taken together, our data suggest that Gi-coupled P2Y receptors are broadly expressed in nociceptors, inhibit nociceptive signaling in vivo, and represent potential targets for the development of novel analgesic drugs.
Malin
Sacha A
SA
Dept Medicine; Dept Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA. sachamalin@gmail.com
Molliver
Derek C
DC
D000818:Animals; D002118:Calcium / Q000378:metabolism; D007150:Immunohistochemistry; D007249:Inflammation / Q000235:genetics / Q000378:metabolism*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D010146:Pain / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D018048:Receptors, Purinergic P2 / Q000235:genetics / Q000378:metabolism*; D058470:Receptors, Purinergic P2Y; D058472:Receptors, Purinergic P2Y1; D058925:Receptors, Purinergic P2Y12; D011984:Sensory Receptor Cells / Q000378:metabolism*; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology
C546383:P2ry1 protein, mouse; C548577:P2ry12 protein, mouse; C486689:P2ry13 protein, mouse; C509795:P2ry14 protein, mouse; D018048:Receptors, Purinergic P2; D058470:Receptors, Purinergic P2Y; D058472:Receptors, Purinergic P2Y1; D058925:Receptors, Purinergic P2Y12; D002118:Calcium
Pain. 2005 Feb;113(3):277-284
15661434
Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):310-23
11111826
Pain. 2008 Sep 15;138(3):484-496
18343036
Cephalalgia. 2004 Apr;24(4):250-61
15030533
Eur J Neurosci. 2002 Nov;16(10):1850-60
12453048
Nat Protoc. 2007;2(1):152-60
17401349
J Neurosci. 2006 Aug 16;26(33):8588-99
16914685
Neuron. 1991 Jan;6(1):13-20
1846076
Nature. 1966 Oct 22;212(5060):411-2
4381910
Br J Pharmacol. 1997 Sep;122(2):365-71
9313948
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10385-90
10468617
Brain Res Rev. 2009 Apr;60(1):24-35
19171165
Neuroscience. 2000;98(3):585-98
10869852
J Neurosci. 2008 May 7;28(19):4949-56
18463248
J Pharmacol Exp Ther. 2002 May;301(2):705-13
11961076
Neurosci Res. 2005 Apr;51(4):405-16
15740803
Eur J Neurosci. 2004 Dec;20(11):2917-28
15579146
Trends Pharmacol Sci. 2003 Feb;24(2):52-5
12559763
J Neurosci Res. 1991 Sep;30(1):92-104
1795410
J Neurosci. 2004 Jan 28;24(4):797-807
14749424
J Pharmacol Exp Ther. 2006 Feb;316(2):556-63
16236815
J Pharmacol Exp Ther. 2004 Dec;311(3):939-47
15280436
J Neurosci. 2008 Mar 12;28(11):2892-902
18337420
Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10465-70
8816824
Br J Pharmacol. 2003 Jan;138(2):343-50
12540525
Pharmacol Rev. 1998 Sep;50(3):413-92
9755289
Nat Med. 1999 Oct;5(10):1199-202
10502826
J Neurosci. 2003 Aug 20;23(20):7479-88
12930786
Neuron. 1998 Sep;21(3):531-43
9768840
Neuroscience. 2002;111(2):413-22
11983326
J Pharmacol Exp Ther. 2008 Feb;324(2):409-15
18042830
Purinergic Signal. 2005 Jun;1(2):193-204
18404504
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6951-6
11371611
J Pharmacol Exp Ther. 2002 Nov;303(2):520-6
12388631
Pain. 2002 Jan;95(1-2):41-7
11790466
J Neurosci. 2004 Feb 18;24(7):1744-53
14973253
J Comp Neurol. 2006 Oct 1;498(4):443-54
16874807
Pain. 2004 Sep;111(1-2):38-50
15327807